Intralipid therapy for unexplained recurrent miscarriage and implantation failure: Case-series and literature review. (September 2020)

• Record Type: Journal Article
• Authors: Plaçais, Léo; Kolanska, Kamilla; Kraiem, Yasmine Ben; Cohen, Jonathan; Suner, Ludovic; Bornes, Marie; Sedille, Lucie; Rosefort, Audrey; D'Argent, Emmanuel Mathieu; Selleret, Lise; Abisror, Noémie; Johanet, Catherine; Buffet, Nathalie Chabbert; Darai, Emile; Antoine, Jean Marie; Fain, Olivier; Kayem, Gilles; Mekinian, Arsène
• Is Part Of: European journal of obstetrics, gynecology, and reproductive biology. Volume 252(2020)
• Page Start: 100
• Page End: 104
• Publication Date: 2020-09
• Subjects: Recurrent miscarriages -- Implantation failure -- Intralipids -- Live birth; Obstetrics -- Periodicals; Gynecology -- Periodicals; Reproductive health -- Periodicals; Gynecology -- Periodicals; Obstetrics -- Periodicals; Reproduction -- Periodicals; Obstétrique -- Périodiques; Gynécologie -- Périodiques; Reproduction -- Périodiques; Verloskunde; Gynaecologie; Voortplanting (biologie); Gynecology; Obstetrics; Reproduction; Electronic journals; Periodicals; Electronic journals; 618.05
• DOI: 10.1016/j.ejogrb.2020.06.017
• Languages: English
• ISSNs: 0301-2115

Abstract

Abstract: Introduction: In retrospective cohort study of women with unexplained recurrent implantation failure (RIF) and miscarriage (RM), we analyzed the efficacy and safety of intralipid therapy to obtain a live birth. Patients and methods: Women with unexplained RM and/or RIF were included from 2015 to 2018 from three French university hospitals. Results: Among 187 women treated for unexplained recurrent miscarriages and implantation failures, 26 women with median age of 36 years (29−43) received intralipid therapy. Among these 26 women, 10 women with a median age of 33 years (31−40) had a history of spontaneous recurrent miscarriages, with a median of 5 (4–8) previous miscarriages. Live births occurred in 7 (70 %) pregnancies under intralipids and were significantly more frequent than in women with recurrent miscarriages who did not receive intralipid therapy (n = 20, p = 0.02). Age, number of previous miscarriages, and additional therapies did not significantly differ between the two groups. Among the 26 included women, 16 had a history of recurrent implantation failures, with median age of 37 years (29−43) and median 9.5 (3–19) embryo transfers. Clinical pregnancy occurred in 9 (56 %) women receiving intralipids after embryo transfers under intralipids among which 5 (55 %) resulted in a live birth. Comparing successful pregnancies under intralipids with those with fetal loss, no significant differences have been noted. Conclusion: Intralipids could be an effective and safe therapy in women with unexplained recurrent miscarriages and infertility.